AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
63 hedge funds and large institutions have $94M invested in AVEO Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 27 closing their positions.
22% more call options, than puts
Call options by funds: $3.77M | Put options by funds: $3.09M
7% less capital invested
Capital invested by funds: $101M → $94M (-$7.32M)
17% less funds holding
Funds holding: 76 → 63 (-13)
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
48% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$12.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.56M |
| 3 |
Millennium Management
New York
|
+$3.24M |
| 4 |
Goldman Sachs
New York
|
+$2.06M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.77M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.18M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.83M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.51M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.37M |
AVEO Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2021, worth a combined $94M — down 7.2% from $101M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of AVEO and 14 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 14 added.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $12.6M. The largest seller was BlackRock, cutting an estimated $7.77M.
- 63 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2021, down from 76 in Q1 2021.
- Funds reported $94M of AVEO Pharmaceuticals, Inc. stock for Q2 2021, down 7.2% quarter-over-quarter.
- 14 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2021 and 27 closed out, a net change of -13 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2021 was J. Goldman & Co, an estimated $12.6M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2021 was BlackRock, an estimated $7.77M sold.
Based on aggregated 13F filings for Q2 2021.